SCHEMBL5952359

SCHEMBL5952359

CCOc1cc2nc(-c3nn(C4CCCCO4)cc3C(N)=O)[nH]c2cc1CC

nearest known ligand 0.34

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PLG P00747 4/20 0.34
PLAU P00749 4/20 0.34
F10 P00742 3/20 0.34
F2 P00734 2/20 0.34
PLAT P00750 2/20 0.34
CHEK2 O96017 3/20 0.34
IRAK4 Q9NWZ3 3/20 0.34
ABL1 P00519 1/20 0.34
ATR Q13535 3/20 0.33
NPC1 O15118 1/20 0.33
TP53 P04637 1/20 0.33
POLB P06746 1/20 0.33
MAPT P10636 1/20 0.33
RAB9A P51151 1/20 0.33
TDP1 Q9NUW8 1/20 0.33
L3MBTL1 Q9Y468 1/20 0.33
KDM5B Q9UGL1 1/20 0.32
KCNH2 Q12809 1/20 0.32
BTK Q06187 1/20 0.32
GCK P35557 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5952513 0.90 EGLN1 (0.37) PLGPLAUF10F2PLAT
SCHEMBL5952289 0.88 ATR (0.35) PLGPLAUF10F2PLAT
SCHEMBL6697073 0.84 ALDH1A1 (0.43) ABL1NPC1POLBMAPTRAB9A
SCHEMBL5952614 0.84 MAPT (0.34) ABL1ATRNPC1POLBMAPT
SCHEMBL5952622 0.82 ATR (0.35) CHEK2ABL1ATRNPC1POLB
SCHEMBL4125202 0.80 CHEK2 (0.38) PLGPLAUF10F2PLAT
SCHEMBL3935957 0.80 CHEK2 (0.40) PLGPLAUF10F2PLAT
SCHEMBL3922498 0.79 CHEK2 (0.41) PLGPLAUF10F2PLAT
SCHEMBL5953369 0.78 JAK2 (0.39) CHEK2ABL1ATRKCNH2BTK
SCHEMBL5951727 0.77 EGLN1 (0.34) PLGPLAUF10F2PLAT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8288425-B2 Benzimidazoles AVENTIS PHARMACEUTICALS INC. (US) 2012-10-16 US disclosed
US-20060014756-A1 Benzimidazoles AVENTIS PHARMACEUTICALS INC. (US) 2006-01-19 US disclosed
US-6897208-B2 Benzimidazoles AVENTIS PHARMACEUTICALS INC. (US) 2005-05-24 US disclosed
EP-1441725-A1 BENZIMIDAZOLES AND ANALOGUES AND THEIR USE AS PROTEIN KINASES INHIBITORS Aventis Pharmaceuticals Inc. (US) 2004-08-04 EP disclosed
US-20040048868-A1 Benzimidazoles AVENTISUB LLC 2004-03-11 US disclosed
WO-2003035065-A1 BENZIMIDAZOLES AND ANALOGUES AND THEIR USE AS PROTEIN KINASES INHIBITORS AVENTIS PHARMACEUTICALS INC (US) 2003-05-01 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060014756-A1 Benzimidazoles CDK9, BMX, SBK3 PLG 975/4885PLAU 2110/4885F10 1209/4885
US-20040048868-A1 Benzimidazoles CDK9, BMX, CDKN1A PLG 1499/4885PLAU 2704/4885F10 961/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.